Table 2.

Therapeutic effects of treatment with pCDR1 on the clinical manifestations of an established experimental SLE

Group	Immunization and treatment	WBC (mean ± SD)	Proteinuria (mean g/l ± SD)	Mean intensity of immune complex deposits ± SD
A	16/6Id	2870  ± 494	1.53  ± 1	1.5  ± 0.2
B	16/6Id + i.v. reversed pCDR1	3120  ± 701	1.67  ± 1.1	1.5  ± 0.5
C	16/6Id + i.v. pCDR1	6200  ± 490*	0.35  ± 0.37†	0.5  ± 0.3‡
D	16/6Id + s.c. pCDR1	5070  ± 625§	0.58  ± 0.36¶	0.66  ± 0.3**
E	Normal mice	7420  ± 511	0.06  ± 0.13	0

BALB/c mice were immunized with 16/6Id. Three and one half months after disease induction, they were treated with either pCDR1 (s.c. or i.v.) or reversed pCDR1 (i.v.) once per week for 10 weeks. Intensity of immune complex deposits were evaluated as described for Table 1. The above results were obtained at sacrifice (about 2 months after treatment had stopped). 

^*, P < 0.01 compared to group A and P < 0.05 compared to group B.  

^‡, P < 0.01 compared to group A and P < 0.05 compared to group B.  

^†, P < 0.02 compared to groups A and B.  

^¶, P < 0.02 compared to groups A and B. ‡, P < 0.03 compared to group A.  

^**, P < 0.03 compared to group A.